OBJECTIVE: To study the pharmacokinetic behaviour of quinine in Caucasians with and without malaria. METHOD: Quinine-dihydrochloride was administered intravenously as a single dose of 300 mg to 12 healthy subjects and as multiple doses of 600 mg in 4 h every 8 h in 10 patients with falciparum malaria. Plasma quinine concentrations were measured by high-performance liquid chromatography RESULTS: Quinine pharmacokinetics are time-dependent: the apparent elimination halftime is shorter in the accumulation phase than in the elimination phase; in malaria patients the maximal quinine concentration was reached in half the time calculated on the basis of the elimination phase after the last quinine infusion. Nevertheless a loading dose seemed advisable to reach adequate therapeutic levels quickly. In malaria patients the highest plasma concentrations during or at the end of the infusions were positively correlated with body weight. There was no correlation between body weight and the volume of distribution of quinine as calculated during the elimination phase. Hearing loss was audiometrically documented in 9 healthy subjects at a mean maximal plasma quinine concentration of only 2 mg/l. All malaria patients suffered serious cochlear hearing impairment. The ototoxic effects in both healthy subjects and patients appeared to be reversible. No electrographic changes were noted in the healthy subjects, whereas a clinically insignificant mean lengthening of the corrected QT interval was seen in the malaria patients. CONCLUSION: Intravenous quinine pharmacokinetics in healthy Caucasians were similar to those reported for Nigerian or Thai subjects. At effective doses quinine causes considerable but reversible cochlear hearing losses in both healthy persons and in patients. Our findings do support the need for a loading dose. The fact that in malaria patients there was no correlation between body weight and quinine VD as calculated during the elimination phase renders questionable the usefulness of dosing quinine according to body weight.
OBJECTIVE: To study the pharmacokinetic behaviour of quinine in Caucasians with and without malaria. METHOD:Quinine-dihydrochloride was administered intravenously as a single dose of 300 mg to 12 healthy subjects and as multiple doses of 600 mg in 4 h every 8 h in 10 patients with falciparum malaria. Plasma quinine concentrations were measured by high-performance liquid chromatography RESULTS:Quinine pharmacokinetics are time-dependent: the apparent elimination halftime is shorter in the accumulation phase than in the elimination phase; in malariapatients the maximal quinine concentration was reached in half the time calculated on the basis of the elimination phase after the last quinine infusion. Nevertheless a loading dose seemed advisable to reach adequate therapeutic levels quickly. In malariapatients the highest plasma concentrations during or at the end of the infusions were positively correlated with body weight. There was no correlation between body weight and the volume of distribution of quinine as calculated during the elimination phase. Hearing loss was audiometrically documented in 9 healthy subjects at a mean maximal plasma quinine concentration of only 2 mg/l. All malariapatients suffered serious cochlear hearing impairment. The ototoxic effects in both healthy subjects and patients appeared to be reversible. No electrographic changes were noted in the healthy subjects, whereas a clinically insignificant mean lengthening of the corrected QT interval was seen in the malariapatients. CONCLUSION: Intravenous quinine pharmacokinetics in healthy Caucasians were similar to those reported for Nigerian or Thai subjects. At effective doses quinine causes considerable but reversible cochlear hearing losses in both healthy persons and in patients. Our findings do support the need for a loading dose. The fact that in malariapatients there was no correlation between body weight and quinine VD as calculated during the elimination phase renders questionable the usefulness of dosing quinine according to body weight.
Authors: Heather A Wroblewski; Richard J Kovacs; Joanna R Kingery; Brian R Overholser; James E Tisdale Journal: Antimicrob Agents Chemother Date: 2012-05-21 Impact factor: 5.191
Authors: Ilse C E Hendriksen; Deogratius Maiga; Martha M Lemnge; George Mtove; Samwel Gesase; Hugh Reyburn; Niklas Lindegardh; Nicholas P J Day; Lorenz von Seidlein; Arjen M Dondorp; Joel Tarning; Nicholas J White Journal: Antimicrob Agents Chemother Date: 2012-11-26 Impact factor: 5.191
Authors: Joachim Schmutzhard; Peter Lackner; Raimund Helbok; Helene Verena Hurth; Fabian Cedric Aregger; Veronika Muigg; Josua Kegele; Sebastian Bunk; Lukas Oberhammer; Natalie Fischer; Leyla Pinggera; Allan Otieno; Bernards Ogutu; Tsiri Agbenyega; Daniel Ansong; Ayola A Adegnika; Saadou Issifou; Patrick Zorowka; Sanjeev Krishna; Benjamin Mordmüller; Erich Schmutzhard; Peter Kremsner Journal: BMC Med Date: 2015-05-28 Impact factor: 8.775
Authors: George O Adjei; Collins Oduro-Boatey; Onike P Rodrigues; Lotte C Hoegberg; Michael Alifrangis; Jorgen A Kurtzhals; Bamenla Q Goka Journal: Malar J Date: 2012-12-17 Impact factor: 2.979
Authors: George O Adjei; Bamenla Q Goka; Emmanuel Kitcher; Onike P Rodrigues; Ebenezer Badoe; Jorgen A L Kurtzhals Journal: J Trop Med Date: 2013-03-07
Authors: Frank Kloprogge; Vincent Jullien; Patrice Piola; Mehul Dhorda; Sulaiman Muwanga; François Nosten; Nicholas P J Day; Nicholas J White; Philippe J Guerin; Joel Tarning Journal: J Antimicrob Chemother Date: 2014-06-25 Impact factor: 5.790